❌ Earnings Miss
Adj. EPS: $(0.06) (vs. $(0.01) est)
YoY: ↓ 200.0% (from $0.06)
❌ Revenue Miss
Sales: $62.20M (vs. $66.34M est)
YoY: ↑ 22.8% (from $50.66M)
Posts
8$XDWH (+0.9%)
$IUHC (+1.05%)
$WHEA (+0.83%)
$WHCS (+0.87%)
$WELS (+0.8%)
$LLY (-2.51%)
$NOVO B (+4.84%)
$RNN519 (+0%)
I would be interested in your opinion on the healthcare sector ? I am currently toying with the idea of parking my cash in the $XDWH (+0.9%) in the health care sector. I believe that the healthcare sector has some catching up to do and if the stock market becomes more volatile, I think the healthcare sector will benefit. Even if it is perhaps only a short-term position, I expect a higher return here than on the call money account. I like the idea, especially as the market for slimming products should continue to grow strongly and $LLY (-2.51%) ubd $NOVO B (+4.84%) will benefit from this as a dominant player.
Added another 300 stock (for a total of 800) of $LFMD with high hopes and expectations. Focus to sell is in 1-2 years, when the company is expected to turn profitable and I am assuming the valuation will jump a lot. May hold for longer, since company may have a bright future ahead of them.
$LFMD earnings highlights for Q1 2025:
LifeMD is expanding access to Wegovy ® for self-pay patients through its virtual care platform by integrating NovoCare ® pharmacy. Eligible patients can now receive all FDA-approved Wegovy doses for $499/month including home delivery - no insurance required.
Source: https://ir.lifemd.com/press-release-details.php?newsId=3070180
LifeMD said Thursday it expanded its insurance acceptance to include Medicare beneficiaries for qualifying virtual primary care, including weight management programs.
The company said over 21 million Medicare Part B beneficiaries in 26 states now have access to virtual care services.
LifeMD said it targets to expand access to medical services to over 60 million Medicare beneficiaries across 49 states by the end of Q2.
LifeMD shares were up more than 2% in recent trading.
Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%
● Adjusted EBITDA increased 78% to $9.0 million
● Telehealth adjusted EBITDA increased 396% to $5.9 million
● Full-year cash flow from operations increased 99% to $17.5 million and generated positive full-year net cash flow
● Exited 2024 with over $35 million in cash
● Introduces 2025 guidance for consolidated revenue of $265 million to $275 million and consolidated adjusted EBITDA of $30 million to $32 million
LifeMD Q4 Adj EPS $(0.02) Beats $(0.05) Estimate
Sales $64.25M Beat $57.38M Estimate
LifeMD Sees Q1 Revenue $61M-$63M Vs $59.447M Est.
FY25 Revenue $265M-$275M Vs $257.23M Est
Top creators this week